All In Biotech

Drug Trial Radar · NCT00887224

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Nov 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 874 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

874

Actual

Start

Jun 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design. Randomized withdrawal means that after receiving desvenlafaxine succinate sustained release for a predetermined period of time, subjects will be selected by chance to either continue receiving the study drug or to be withdrawn from the study drug and receive placebo for the remainder of their participation in the trial. Subjects will not know to which group they have been assigned. The study consists of an up to 14-day screening period followed by an 8-week open-label period in which subjects will knowingly receive 50 mg/day of desvenlafaxine succinate sustained release. Subjects who do not respond to treatment, demonstrating no significant change in their depressive symptoms, will be withdrawn from participation at the end of this period. Responding subjects will receive an additional 3 months of open-label desvenlafaxine succinate sustained release at the same dose. Subjects with stable response to treatment at the conclusion of this 3 month period will be randomized to either desvenlafaxine succinate sustained release at 50 mg/day or placebo in a blinded manner for an additional 6 months or until symptoms of depression return. Following discontinuation at any point after enrollment in the study, subjects will receive two weeks of follow-up monitoring, including one week of blinded taper with 25 mg/day of desvenlafaxine succinate sustained release treatment for any subjects who have been taking desvenlafaxine succinate sustained release prior to discontinuation. Subjects assigned to placebo will receive a blinded placebo taper. Following taper, subjects will be evaluated for one additional week to monitor safety.

Conditions

  • Major Depressive Disorder

Interventions

  • Desvenlafaxine succinate sustained release 50 mgDrug

    50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.

  • Desvenlafaxine succinate sustained release 25 mgDrug

    25 mg tablet for taper, once daily for 1 week

  • PlaceboDrug

    Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185Time frame: Double-blind phase Baseline (Study Day 140) up to DB Day 185 (Study Day 325)

Locations

90 sites in 14 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Beverly Hills, California

  • Pfizer Investigational Site

    Encino, California

  • Pfizer Investigational Site

    Los Alamitos, California

  • Pfizer Investigational Site

    Orange, California

  • Pfizer Investigational Site

    Upland, California

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    South Miami, Florida

  • Pfizer Investigational Site

    St. Petersburg, Florida

  • Pfizer Investigational Site

    St. Petersburg, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Smyrna, Georgia

  • Pfizer Investigational Site

    Hoffman Estates, Illinois

  • Pfizer Investigational Site

    Rockville, Maryland

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Rochester, New York

  • Pfizer Investigational Site

    Dayton, Ohio

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    San Antonio, Texas

  • Pfizer Investigational Site

    Seattle, Washington

  • Pfizer Investigational Site

    Edmonton, Alberta, Canada

  • Pfizer Investigational Site

    Medicine Hat, Alberta, Canada

  • Pfizer Investigational Site

    Kelowna, British Columbia, Canada

  • Pfizer Investigational Site

    Vancouver, British Columbia, Canada

  • Pfizer Investigational Site

    Bathurst, New Brunswick, Canada

  • Pfizer Investigational Site

    Burlington, Ontario, Canada

  • Pfizer Investigational Site

    Ottawa, Ontario, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Gatineau, Quebec, Canada

  • Pfizer Investigational Site

    Pointe-Claire, Quebec, Canada

  • Pfizer Investigational Site

    Sherbrooke, Quebec, Canada

  • Pfizer Investigational Site

    Santiago, Chile, Chile

  • Pfizer Investigational Site

    Santiago, Chile, Chile

  • Pfizer Investigational Site

    Santiago, Chile, Chile

  • Pfizer Investigational Site

    Medellín, Antioquia, Colombia

  • Pfizer Investigational Site

    Barranquilla, Atlántico, Colombia

  • Pfizer Investigational Site

    Bogota, Cundinamarca, Colombia

  • Pfizer Investigational Site

    Bucamaranga, Santander Department, Colombia

  • Pfizer Investigational Site

    Rijeka, Croatia

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.